Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user!
Twitter Inc (NYSE:TWTR) and Facebook, Inc. (NASDAQ:FB) were trading marginally lower. Executives from the two social media giants will testify before Congress and are expected to discuss multiple topics ranging from election interference to allegations of a bias slant against conservatives on their platform.
Tesla Inc (NASDAQ:TSLA) was trading lower by 1.3 percent after Mercedes Benz introduced a potential rival to its SUV. The German-based automaker plans to invest $12 billion in its electric-vehicle lineup, including the recently announced EQC crossover which will start production next year.
JD.Com Inc(ADR) (NASDAQ:JD) was trading lower by nearly 5 percent amid ongoing headline concerns involving its CEO Richard Liu. The Chinese billionaire was arrested Friday in Minnesota on suspicion of assault but was released the next day and returned to China. According to a police report obtained by The Washington Post, the executive was detained by police in Minnesota on allegations of rape rather than initial reports of assault.
Histogenics Corp (NASDAQ:HSGX) lost around 75 percent after the developer of restorative cell therapies announced a disappointing update to a clinical trial. The company said a phase 3 trial of its NeoCart therapy failed to achieve the primary endpoint of showing a statistically significant improvement in pain and function among patients one year after treatment.
ProQR Therapeutics NV (NASDAQ:PRQR) gained around 70 percent after the developer of RNA medicines for the treatment of severe genetic rare diseases announced an update to a clinical trial. The company said interim results from a phase 1/2 trial of its QR-110 therapy for patients with Leber's congenital amaurosis showed a "meaningful improvement in vision in the treated eye as measured by both mechanistic and potential registration endpoints."
Related Links:
26 Stocks Moving In Wednesday's Pre-Market Session
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!